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Background: Tubular dysfunction is common in HIV-infected people and detection of proteinuria is essential to
identify this problem. In low-income countries, resources for detection of proteinuria using the Kidney Disease
Improve Global Outcomes (KDIGO) gold standard urinary protein/creatinine ratio (uPCR) is rarely possible, and
use of the protein reagent strip (PRS) could be an option in these places. The aims of this study were to establish
the concordance between PRS and uPCR to detect tubular proteinuria in HIV-infected people, and to assess the
sensitivity and specificity of PRS as a diagnostic method in this group.
Methods: A cross-sectional study was conducted to evaluate the correlation between the two techniques to detect
protein in urine. Participants were enrolled for a period of 6 months. The measurements were performed in participants
who were on highly active antiretroviral therapy (HAART) or prior to the start of treatment. Proteinuria was defined as
uPCR≥ 150 mg/g, and/or≥ trace on PRS. A phi coefficient was calculated to establish the degree of correlation. We
assessed the sensitivity and specificity of PRS compared with uPCR using standard methods.
Results: A total of 799 subjects were included. Of these, 737 (92%) were men. The mean age was 32.9 years
(±10.1 years). Most (561, 70%) were on antiretroviral treatment. The mean estimated glomerular filtration rate (eGFR)
calculated according to Modification of Diet in Renal Disease (MDRD)-4 was 113.0 mL/min (±22.6). Comorbidities
included diabetes mellitus (10, 1.3%) and hypertension (17, 2.1%). The prevalence of proteinuria detected by PRS was
8.3% (n = 66) and by uPCR 10.6% (n = 85). The concordance assessed by phi correlation coefficient was 0.70, p < 0.001,
with a sensitivity of 51.7% (95% confidence interval [CI] 41%–62%) and specificity 97% (95% CI 39%–97%).
Conclusions: There is a high concordance between detection of proteinuria by PRS and uPCR. Therefore, in
low-income countries PRS can be helpful for detecting tubular damage in people infected with HIV.
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Kidney disease is a complication that is observed in
10%–30% of patients infected with human immunodefi-
ciency virus (HIV), and is a common cause of morbidity
and mortality [1,2]. In Mexico, an estimated 175,093
HIV-infected individuals are included in national registries* Correspondence: Ignaciof4@hotmail.com
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article, unless otherwise stated.[3]. The increased survival of HIV-infected patients has
changed the course of the disease, with renal complications
related to HIV now the fourth most common cause of
mortality [4].
The prevalence of chronic kidney disease (CKD) in
HIV-infected patients is 2%–10% [5], although some
studies have estimated that 24% of HIV-infected patients
have a baseline GFR < 90 mL/min [6,7]. Persistent
proteinuria is the principal marker of glomerular and
tubular disease in people with HIV/acquired immuneCentral. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Table 1 Demographic characteristics of the study
population




Age, years (mean ± SD) 32.9 ± 10.1
BMI (mean ± SD) 23.8 ± 2.8
Participants on HAART n (%) 561 (70.2%)
eGFR calculated using MDRD-4 mL/min
(mean ± SD)
113.06 ± 22.6
Diabetes n (%) 10 (1.3%)
Hypertension n (%) 17 (2.1%)
BMI: body mass index; HAART: highly-active antiretroviral therapy; eGFR: estimated
glomerular filtration rate; MDRD: modification of diet in renal disease.
Table 2 Results
uPCR significant uPCR not significant Total
Proteinuria in PRS 44 22 66
No proteinuria in PRS 41 692 733
Total 85 714 799
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early identification of renal disease [8-10]. The Infectious
Disease Society of America recommends that at the time
of HIV diagnosis, all individuals should be assessed for
kidney disease by a screening urine analysis for protein-
uria, and that those with proteinuria should be referred
for early treatment to prevent kidney failure [11].
To evaluate primary tubular and glomerular abnormal-
ities, a specific and early screening process is required. It
is generally accepted that measurement of the urine
protein/creatinine ratio (uPCR) and the urine albumin/
creatinine ratio (uACR) constitute a relatively inexpen-
sive and effective method [12]. Proteinuria is defined as
uPCR ≥ 150 mg/g on more than two occasions separated
by 2–3 weeks [13]. The uPCR ratio was found to be
74.4%–90% sensitive and 93%–98% specific for the diag-
nosis of proteinuria of 0.5–2 g/day [14]. The protein
reagent strip (PRS) can also be used to screen for pro-
teinuria, and its sensitivity and specificity range from
80%–97% and 33%–80%, respectively [15]. In a rapid
urine test, uPCR is preferred to uACR because it detects
total urinary protein secondary to glomerular and tubu-
lar disease.
Some studies suggest that the use of test strips as a
screening method increases by 13%–44% the likelihood
of identifying a rapid deterioration in renal function in
high-risk populations [16,17], dipstick false positive re-
sults have been found in association with dehydration
(that increase the urine protein concentration, mainly al-
bumin), exercise, hematuria, urinary tract infections,
highly alkaline urines (pH 8); false-negative results are
associated with excessive diuresis by overhydration and
with proteins that do not have reactions with the dip-
stick (e.g. monoclonal proteins) [18]. The aims of this
study were to establish a concordance between PRS and
uPCR for detection of tubular proteinuria in HIV-
infected people and to assess the sensitivity and specifi-
city of PRS as a diagnostic method in this group.
Results
A total of 799 HIV-infected patients were included, of
whom 737 were men (92%). The mean age was 32.9 years
(SD ± 10.1 years). Most participants (561, 70%) were on
antiretroviral treatment.
The median eGFR calculated according to MDRD-4
was 113.06 mL/min (±22.62 mL/min), with 691 (86.48%)
participants in MDRD-4 stage 1, 104 (13.01%) in stage 2,
and 4 (0.50%) in stage 3. Ten participants (1.3%) had
diabetes mellitus and 17 (2.1%) had hypertension
(Table 1). The prevalence of proteinuria detected by
dipstick was 8.3% (n = 66) and by uPCR was 10.6%
(n = 85) [Table 2]. The concordance between PRS and
uPCR assessed by the phi correlation coefficient was 0.7,
p < 0.001.When we evaluated the use of PRS to diagnose
proteinuria, we found a sensitivity of 51.7% (95% confi-
dence interval [CI] 41.3%–62%), specificity 97.2% (95%
CI 95.3%–97.9%), positive predictive value 66.6% (95% CI
54.6%–76.8%), negative predictive value 94.4% (95% CI
92.5%–95.8%), positive likelihood ratio 18.4, and negative
likelihood ratio 0.49 (0.52–0.94).
Discussion
CKD is currently the fourth leading cause of morbidity
and mortality in HIV-infected patients. One of the main
factors determining progression of CKD is proteinuria
from any source; therefore, it is important to apply diag-
nostic methods such as uPCR that allow us to identify
proteinuria in HIV-infected people. Although this point
is noted in the most recent European AIDS Clinical
Society 2013 guidelines, unfortunately it is not always
possible to carry out this testing in developing countries,
where access to healthcare is limited. Not because of the
reagent cost, but the uPCR test is not available in most
of the clinical setting. For this reason it is important to
evaluate other diagnostic options that are available to a
greater number of people and medical centers, including
diagnostic methods with high sensitivity and specificity
that are comparable to the gold standard defined accord-
ing to the Kidney Disease Improving Global Outcomes
2012 guidelines, such as the use of PRS for detecting
proteinuria.
In our study, the population was composed mainly of
men in the third decade of life, most of them with
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mented in approximately 10% by uPCR. We found a
strong positive correlation between PRS and uPCR re-
sults and a high specificity and negative predictive value
of PRS for detection of proteinuria in HIV-infected pa-
tients. These data suggest that a negative PRS result is
useful to exclude disease and a positive PRS is associated
with high probability of the presence of disease.
This result is consistent with other reports that PRS
results are useful mainly when proteinuria exceeds 300–
500 mg/day, that they correlate well with the uPCR, and
have a low positive predictive value and a high negative
predictive value [19-21]. However, Realston et al. re-
ported that PRS testing had a sensitivity of 100% and a
high incidence of false positives (48%) at low levels of
proteinuria [22]. The high sensitivity in that study was
linked to the methodology used, as only patients with a
trace or more of protein were included, in contrast to
our study in which all participants with or without traces
of protein were included, allowing a better determin-
ation of the correlation between the two diagnostic
methods.
In another study in pregnant women, the positive pre-
dictive value of PRS ranged from 64.9% (single voided
urine sample) to 94.2% (24-hour urine aliquot) and the
negative predictive value ranged from 75.2% (single
voided urine sample) to 84.2% (24-hour urine aliquot),
with the authors concluding that PRS had low accuracy
as a screening method [23].
The usefulness of proteinuria determined by PRS as a
risk factor for development and progression of chronic
kidney disease is supported by the data published by
Iseki et al. [24] and Gomez de Mattos Cavalcante et al.
[25], who demonstrated that proteinuria assessed by PRS
is an independent risk factor for end-stage renal disease,
with a cumulative incidence of 1.4% with proteinuria
(1+) and 7.1% with proteinuria (2+) at 17 years of
follow-up.
The main strength of this study is the population size
and the homogeneity of the sample: most of the popula-
tion constituted men in the third decade of life with nor-
mal renal function, only four had stage 3 CKD, and
there was a low prevalence of comorbidities at the time
of the study. Statistical analysis supports the conclusion
that there is a high correlation between quantitative and
qualitative methods for the detection of proteinuria, with
a phi correlation coefficient close to one. We also evalu-
ated the sensitivity and specificity of PRS in HIV-
infected patients with robust statistical likelihood testing,
which provides a qualitative determination of the high
value of detecting the presence of protein in urine. Most
of the previously mentioned studies included healthy or
pregnant individuals or those with various comorbidities
including nephropathy, autoimmune diseases, and others.Only a few studies have focused on the analysis of protein-
uria and diagnostic methods and their effectiveness in
HIV-infected patients [26,27], which made similar conclu-
sions to ours, considering PRS a method with low sensitiv-
ity but with a good correlation with uPCR, due to the
presence of different proteins, instead of albumin. Siedner
et al. reported greater sensitivity with a higher uPCR
(≥300 mg/g); however, in our study the cut-off point was
150 mg/g, therefore, the sensibility is compromised but
the specificity is better.. However because of the similarity
with previous studies we expect a similar behavior, so con-
sidering 300 mg/g as a cutoff we would expect that the
positive predictive value and sensitivity also increase.
Guidelines for the management of chronic kidney
disease in patients with HIV issued by the Infectious
Diseases Society of America recommend that urine dip-
stick tests should be used to detect kidney abnormalities
in this population [1].
This test should have the ability to detect kidney dis-
ease with a threshold of 1+ proteinuria, but dipstick tests
measure levels of albumin, and if urine is diluted the ac-
curacy of these tests is affected. Furthermore, some types
of kidney disease, including tubular disorders, cannot be
accurately diagnosed using dipstick tests.
The majority of the participants in this study has a
preserved GFR, indicating a minimal glomerular dam-
age, so the proteinuria would mainly be tubular not
glomerular.
We did not find any study in Mexico addressing PRS
as a diagnostic test in HIV-infected individuals, a ques-
tion that we believe is very important because of the
high risk of proteinuria in this specific population.
Regarding the limitations of the study, first, measure-
ment of proteinuria by PRS is susceptible to errors de-
pending on the observer, sample handling, and the
quality of the test strips. Additional participant informa-
tion including the type of antiretroviral treatment and
its duration, or the time from diagnosis of the disease,
were not considered in this study, which focused only
on the correlation between two diagnostic methods and
not on factors associated with the onset of proteinuria.
Further studies evaluating these points should be consid-
ered. We could not evaluate the type of antiretroviral
therapy with the PRS or uPCR, in addition, the associ-
ation of TDF with the abnormalities found in this test
was not measured.
Finally, based on the results of this study, we suggest
that the correlation between uPCR and PRS is strong
enough to consider the latter a cost-effective diagnostic
method applicable to our population.
In future studies is necessary to take in to consider-
ation the degree of proteinuria in dipstick, classifying
according to the number of + of proteins, as well as in-
creasing uPCR cut off point and avoiding or decreasing
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ing the clinical state of the patients at the moment of
sampling.Conclusions
There is a high concordance between detection of pro-
teinuria by PRS and uPCR with a fair sensitivity, high
specificity, and negative predictive values for PRS. Al-
though the qualitative method is not better for screening
than the quantitative method, in low-income countries,
PRS analysis can be a useful tool to detect tubular dam-
age in HIV-infected individuals.Methods
Study design
After obtaining approval for the research protocol from
the Ethics and Investigation Committee of “La Raza”
National Medical Center (approval number R-2014-
3502-147), we conducted a cross-sectional study be-
tween August 2012 and December 2013 at Hospital de
Infectología “La Raza” in Mexico City.Participants
The sample included treatment-naïve and treatment-
experienced HIV-infected patients aged between 17 and
79 years who attended the HIV clinic and who under-
went PRS and quantitative urine protein determinations,
treatment regimen was not recorded. We excluded
individuals with overt hematuria. Individuals were also
excluded if they withdrew their informed consent.
After obtaining informed consent, each participant was
interviewed, and information including age and current
chronic diseases was recorded on the designated record
forms.Measurements
The enrolled participants were assessed for weight,
height, and antiretroviral treatment. Serum creatinine
was measured by the chemiluminescence method.
Urine creatinine was measured quantitatively using a
photometric method, and urine total protein was
measured quantitatively using a turbidimetric procedure;
a Multistix 10 SG (SIEMENS®) reagent strip was used for
qualitative assessment, evaluating the presence of pro-
teinuria, with 1+ or more. Estimated glomerular filtra-
tion rate (eGFR) in mL/min was calculated using the
Modification of Diet and in Renal Disease-4 (MDRD-4).
We defined proteinuria as uPCR ≥ 150 mg/g and ≥ trace
on PRS, the time between samples for each test was
less than 24 h, and in most of the patients both tests
were done with the same urine sample.Statistical analysis
Statistical analysis was performed using the Statistical
Package for Social Sciences (SPSS) software, version 21
(IBM, Armonk, NY). Descriptive statistics were used to
evaluate the demographic characteristics of the study
population; because the continuous variables that were
analyzed were normally distributed, the mean and stand-
ard deviation were used. A phi coefficient was calculated
to establish the degree of correlation. Using standard
methods we assessed the sensitivity, specificity, and posi-
tive and negative predictive values of PRS by comparison
with uPCR as a gold standard. A value of p < 0.05 was
considered significant.
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